GAMIDA CELL LTD (GMDA)
IL0011552663 - Common Stock
GMDA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. GMDA may be in some trouble as it scores bad on both profitability and health. GMDA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
GMDA had negative earnings in the past year.
In the past year GMDA has reported a negative cash flow from operations.
In the past 5 years GMDA always reported negative net income.
In the past 5 years GMDA always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -61.65%, GMDA is not doing good in the industry: 60.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.65% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-61.87%
ROA(5y)-54.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 18.53%, GMDA is in the better half of the industry, outperforming 75.47% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for GMDA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GMDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GMDA has more shares outstanding
GMDA has more shares outstanding than it did 5 years ago.
GMDA has a worse debt/assets ratio than last year.
2.2 Solvency
GMDA has an Altman-Z score of -8.53. This is a bad value and indicates that GMDA is not financially healthy and even has some risk of bankruptcy.
GMDA has a worse Altman-Z score (-8.53) than 74.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.53 |
ROIC/WACCN/A
WACC5.78%
2.3 Liquidity
GMDA has a Current Ratio of 2.16. This indicates that GMDA is financially healthy and has no problem in meeting its short term obligations.
GMDA's Current ratio of 2.16 is on the low side compared to the rest of the industry. GMDA is outperformed by 75.98% of its industry peers.
GMDA has a Quick Ratio of 2.09. This indicates that GMDA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.09, GMDA is doing worse than 75.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.16 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
GMDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.19%, which is quite impressive.
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q86.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 50.79% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 182.44% on average over the next years. This is a very strong growth
EPS Next Y9.37%
EPS Next 2Y50.84%
EPS Next 3Y51.21%
EPS Next 5Y50.79%
Revenue Next Year808.75%
Revenue Next 2Y935.67%
Revenue Next 3Y499.3%
Revenue Next 5Y182.44%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GMDA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GMDA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GMDA's earnings are expected to grow with 51.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.84%
EPS Next 3Y51.21%
5. Dividend
5.1 Amount
No dividends for GMDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GAMIDA CELL LTD
NASDAQ:GMDA (4/5/2024, 7:00:00 PM)
After market: 0.032 0 (-2.14%)0.0327
-0.01 (-18.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.65% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.53% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.16 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)49.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y